1. Laxminarayan, R., Wahl, B., Dudala, S.R., Gopal, K., Neelima, S., Reddy, K.J., Radhakrishnan, J. and Lewnard, J.A., 2020. Epidemiology and transmission dynamics of COVID-19 in two Indian states. Science, 370(6517), 691-697.
2. Liang, L.L., Kuo, H.S., Ho, H.J. and Wu, C.Y., 2021. COVID-19 vaccinations are associated with reduced fatality rates: Evidence from cross-county quasi-experiments. Journal of Global Health, 11.
3. Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K.S., Lau, E.H., Wong, J.Y. and Xing, X., 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England journal of medicine., 1199–1207
4. Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X. and Guan, L., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 395(10229), 1054-1062
5. Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L., Hui, D.S. and Du, B., 2020. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 382(18),1708-1720.
6. Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R. and Iotti, G., 2020. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. Jama, 323(16), 1574-1581.
7. Docherty, A.B., Harrison, E.M., Green, C.A., Hardwick, H.E., Pius, R., Norman, L., Holden, K.A., Read, J.M., Dondelinger, F., Carson, G. and Merson, L., 2020. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. bmj, 369.
8. Richardson, S., Hirsch, J.S., Narasimhan, M., Crawford, J.M., McGinn, T., Davidson, K.W., Barnaby, D.P., Becker, L.B., Chelico, J.D., Cohen, S.L. and Cookingham, J., 2020. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama, 323(20), 2052-2059.
9. Petrilli, C.M., Jones, S.A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K.A., Cerfolio, R.J., Francois, F. and Horwitz, L.I., 2020. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. Bmj, 369.
10. Lewnard, J.A., Liu, V.X., Jackson, M.L., Schmidt, M.A., Jewell, B.L., Flores, J.P., Jentz, C., Northrup, G.R., Mahmud, A., Reingold, A.L. and Petersen, M., 2020. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. bmj, 369.
11. Dong, E., Du, H. and Gardner, L., 2020. An interactive web-based dashboard to track COVID-19 in real time. The Lancet infectious diseases, 20(5), 533-534.
12. Clark, A., Jit, M., Warren-Gash, C., Guthrie, B., Wang, H.H., Mercer, S.W., Sanderson, C., McKee, M., Troeger, C., Ong, K.L. and Checchi, F., 2020. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet Global Health, 8(8), e1003-e1017.
13. Coronavirus disease (COVID-19) situation report 209”(World Health Organization, 16 August 2020); www.who.int/docs/default-source/coronaviruse/situation-reports/20200816-covid-19-sitrep-209.pdf?sfvrsn=5dde1ca2_2.
14. Walker, P.G., Whittaker, C., Watson, O.J., Baguelin, M., Winskill, P., Hamlet, A., Djafaara, B.A., Cucunubá, Z., Olivera Mesa, D., Green, W. and Thompson, H., 2020. The impact of COVID-19 and strategies for mitigation and suppression in low-and middle-income countries. Science, 369(6502), 413-422.
15. Gilbert, M., Pullano, G., Pinotti, F., Valdano, E., Poletto, C., Boëlle, P.Y., d'Ortenzio, E., Yazdanpanah, Y., Eholie, S.P., Altmann, M. and Gutierrez, B., 2020. Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. The Lancet, 395(10227), 871-877.
16. Davies, N.G., Klepac, P., Liu, Y., Prem, K., Jit, M. and Eggo, R.M., 2020. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nature medicine, 26(8), 1205-1211.
17. Gupta, M., Wahl, B., Adhikari, B., Bar-Zeev, N., Bhandari, S., Coria, A., Erchick, D.J., Gupta, N., Hariyani, S., Kagucia, E.W. and Killewo, J., 2020. The need for COVID-19 research in low-and middle-income countries. Global Health Research and Policy, 5(1), 1-4.
18. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. doi: 10.1001/jama.2020.1585.
19. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y. and Yu, T., 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet, 395(10223), 507-513.
20. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Geneva: WHO; 2020. Available from: https://www.who.int/docs/default-source/ coronaviruse/clinical-management-of-novel-cov.pdf, accessed on February 16, 2020.
21. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X. and Cheng, Z., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223),497-506.
22. Duan YN, Qin J. Pre- and posttreatment chest CT findings: 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 2020. Do https://doi.org/10.1148/radiol.2020200323.
23. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.06 20020974.
24. Cori, A., Ferguson, N.M., Fraser, C. and Cauchemez, S., 2013. A new framework and software to estimate time-varying reproduction numbers during epidemics. American journal of epidemiology, 178(9), 1505-1512.
25. Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Marc, G.P., Moreira, E.D., Zerbini, C. and Bailey, R., 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine.
26. Hodgson, S.H., Mansatta, K., Mallett, G., Harris, V., Emary, K.R. and Pollard, A.J., 2021. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The lancet infectious diseases, 21(2), e26-e35.
27. Harvey, W.R., 1990. User’s Guide for LSMLMW. Mixed Model Least-squares and Maximum Likelihood Computer Program. PC I Version, Ohio State University, Columbus. Egyptian J. Anim. Prod.(1996), 15.
28. Wu, Z. and McGoogan, J.M., 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. jama, 323(13), 1239-1242.
29. Patel, A.B. and Verma, A., 2020. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?. Jama, 323(18), pp.1769-1770.
30. Tiganelli C.J., Ingraham N.E., Sparks M.A., Benson B., Schacker T., Chipman J., Puskarich M.A. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med. 2020 doi: 10.1016/S2213-2600(20)30153-3.
31. Countries where coronavirus has spread - Worldometer. Available from: https://www.worldometers.info/coronavirus/ countries-where-coronavirus-has-spread/, accessed on February 28, 2020.
32. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report WHO; 2020. https://who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
33. COVID, C., Team, R., Jorden, M.A., Rudman, S.L., Villarino, E., Hoferka, S., Patel, M.T., Bemis, K., Simmons, C.R., Jespersen, M. and Johnson, J.I., 2020. Evidence for limited early spread of COVID-19 within the United States, January–February 2020. Morbidity and Mortality Weekly Report, 69(22), p.680.
34. Khafaie, M.A. and Rahim, F., 2020. Cross-country comparison of case fatality rates of COVID-19/SARS-COV-2. Osong Public Health and Research Perspectives, 11(2), 74.
35. Öztoprak, Fadime, and Aadil Javed. "Case fatality rate estimation of COVID-19 for European countries: Turkey’s current scenario amidst a global pandemic; comparison of outbreaks with European countries." EJMO 4, no. 2 (2020): 149-159.
36. Chatterjee, P., Nagi, N., Agarwal, A., Das, B., Banerjee, S., Sarkar, S., Gupta, N. and Gangakhedkar, R.R., 2020. The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence. The Indian journal of medical research, 151(2-3), 147.
37. Singh, A.K., Gupta, R., Ghosh, A. and Misra, A., 2020. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14(4), pp.303-310.
38. Zhao, Q., Meng, M., Kumar, R., Wu, Y., Huang, J., Lian, N., Deng, Y. and Lin, S., 2020. The impact of COPD and smoking history on the severity of COVID‐19: A systemic review and meta‐analysis. Journal of medical virology, 92(10), pp.1915-1921.
39. CDC. Coronavirus (COVID-19): symptoms of coronavirus. Centers for Disease Control and Prevention. 2020.
40. BCCDC. COVID-19 vulnerable populations. British Columbia Centre for Disease Control. 2020. [Accessed April 18, 2020, http://www.bccdc.ca/health-info/diseases-conditions/covid-19/vulnerable-populations].
41. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-23.
42. Haas, E.J., Angulo, F.J., McLaughlin, J.M., Anis, E., Singer, S.R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K. and Southern, J., 2021. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet, 397(10287), 1819-1829.
43. Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19). Factsheet for healthcare providers administering vaccine. https://www.fda.gov/media/144637/download?utm_medium=email&utm_source=govdelivery (Accessed on October 21, 2021).
44. US FDA. Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). https://www.fda.gov/media/146304/download (Accessed on October 21, 2021)
45. Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y. and Leshem, E., 2021. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. The Lancet, 397(10277), pp.875-877.
46. Hunter, P.R. and Brainard, J.S., 2021. Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of'real-world'vaccination outcomes from Israel. Medrxiv.. 2021;2021.02.01.21250957.
47. Chodick, G., Tene, L., Patalon, T., Gazit, S., Tov, A.B., Cohen, D. and Muhsen, K., 2021. Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. JAMA network open, 4(6), pp.e2115985-e2115985.
48. Benenson, S., Oster, Y., Cohen, M.J. and Nir-Paz, R., 2021. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers. New England Journal of Medicine, 384(18), pp.1775-1777.
49. Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012–2019.
50. Zhou F, Yu T, Du R, Fan G, Liu F, et al., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395(10229):1054–1062.
51. Russell, T.W., Hellewell, J., Jarvis, C.I., Van Zandvoort, K., Abbott, S., Ratnayake, R., Flasche, S., Eggo, R.M., Edmunds, W.J., Kucharski, A.J. and CMMID COVID-19 working group, 2020. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Eurosurveillance, 25(12), p.2000256.
52. Tisminetzky, M., Delude, C., Hebert, T., Carr, C., Goldberg, R.J. and Gurwitz, J.H., 2022. Age, multiple chronic conditions, and COVID-19: a literature review. The Journals of Gerontology: Series A, 77(4), 872-878.
53. Battegay, M., Kuehl, R., Tschudin-Sutter, S., Hirsch, H.H., Widmer, A.F. and Neher, R.A., 2020. 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate–a word of caution. Swiss medical weekly, 150(0506).
54. Kang, Y.J., 2020. Mortality rate of infection with COVID-19 in Korea from the perspective of underlying disease. Disaster medicine and public health preparedness, 14(3), 384-386.
55. Molenberghs, G., Faes, C., Verbeeck, J., Deboosere, P., Abrams, S., Willem, L., Aerts, J., Theeten, H., Devleesschauwer, B., Sierra, N.B. and Renard, F., 2022. COVID-19 mortality, excess mortality, deaths per million and infection fatality ratio, Belgium, 9 March 2020 to 28 June 2020. Eurosurveillance, 27(7), p.2002060.
56. Iype, E. and Gulati, S., 2020. Understanding the asymmetric spread and case fatality rate (CFR) for COVID-19 among countries. MedRxiv.